Date & time
Thursday, February 13, 2020
4:30 p.m. – 6:30 p.m.
4:30 p.m. – 6:30 p.m.
Workshops & seminars
Share this event:
Biotalk Café: From Lab to Market with Repare Therapeutics
Using CRISPR-enabled gene editing for the discovery of novel precision oncology drug targets
Cost
This event is free
Organization
Contact
Where
J.W. McConnell Building
1400 De Maisonneuve Blvd. W.
4TH SPACE
Wheel chair accessible
Yes
Join us on February 13th to hear from Jordan Young, PhD, from Repare Therapeutics, a Montreal & Boston based leading biotech company in the field of precision oncology that recently raised US$82.5M in series B financing. Jordan joined Repare Therapeutics in 2017 to lead an innovative Target Discovery Platform called SNIPRx™. This platform combines CRISPR-enabled gene editing, computation biology, and clinical informatics to identify mutations in cancer cells that would allow precision oncology drugs to be toxic to cancer cells but harmless to normal cells.
During this talk, Jordan Young will share the story of Repare Therapeutics and describe how the technology developed by 3 scientists became one of the top academic spinouts of 2017, according to Nature Biotechnology. Jordan will also describe how Repare’s platform uses CRISPR to discover new drug targets and how it can help identifying patients that are more likely to respond to precision oncology drugs.
Students, researchers, and entrepreneurs are welcome to participate in this dialogue for the advancement of impactful technologies to develop precisely targeted cancer therapies that save lives.
About Jordan Young
Jordan Young completed his PhD at the University of Toronto in Daniel Durocher’s laboratory, where he mapped synthetic lethal interactions for DNA repair factors using CRISPR-enabled genetic screens.
About Repare Therapeutics
Repare Therapeutics is a 2017 “Fierce 15” drug discovery company backed by tier-one strategic and institutional biotechnology investors. Repare Therapeutics is developing new, precision oncology drugs for patients that target specific vulnerabilities of tumour cells. Its approach integrates insights from several fields of cell biology including DNA repair and synthetic lethality. Repare’s SNIPRx™ platform combines a proprietary, high-throughput, CRISPR-enabled gene editing target discovery method with high-resolution protein crystallography, computational biology and clinical informatics.